Assessment of Transcultural Psychotherapy in Child Major Depressive Disorder
Condition(s) studied
Investigational drug(s) / intervention(s)
Transcultural psychotherapy: In addition to usual care, the participants receive transcultural psychotherapy
Study summary
The symptomatic and clinical expression of psychiatric disorders in children and adolescents is strongly influenced by the cultural setting they are growing up in. These cultural variations complicate psychiatric care, especially for migrant children, for whom appropriate care must be designed.
Transcultural psychotherapy is an original psychotherapeutic technique developed to meet these specific requirements in France and in different European and American countries. Its theoretical and methodological foundations rest on the works of George Devereux in ethnopsychiatry (1970). A psychotherapeutic technique intended for first-generation migrants was developed by Tobie Nathan and coll (1986). Marie-Rose Moro and colleagues (1990) have adapted this technique to second-generation migrants.
Indicated as a second-line treatment after the failure of standard management, this technique is fully formalized today. It comprises group consultations for the child and the family as a one-hour session each month, directed by a principal therapist, assisted by a group of co-therapists (of diverse cultural origins and occupations) and an interpreter in the family's mother tongue. The concept of culture is used to establish the therapeutic alliance, decode the symptoms, and propose treatment.
The children and adolescents receiving this treatment have varied psychopathological profiles, mostly involving depressive and/or anxiety disorders. Specifically, migrants' children are especially vulnerable to depression, their psychiatric care is generally longer and less effective than in the general population, and their rate of treatment failure higher.
Transcultural psychotherapy has demonstrated its value in these situations in numerous qualitative studies, but its efficacy has not yet been assessed by a method providing a high level of evidence, such as randomized controlled trials.
Eligibility
Primary outcome measure(s)
- Severity Score on the Improved Global Impression Scale (iCGI) to assess remission — at week 34 visit (v5)
.iCGI score is a scale ranging from 1 to 7, 1 being Normal, not at all ill, and 7 - Among the most extremely ill patients. 1. \- Normal, not at all ill 2. \- Borderline mentally ill 3. \- Mildly ill 4. \- Moderately ill 5. \- Markedly ill 6. \- Severely ill 7. \- Among the most extremely ill patients Remission is defined as a mean iCGI score over the 3 experts \<4 at 28 weeks of treatment (W34).
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Service de Psychopathologie de l'enfant, de l'adolescent, CHU Avicenne | Bobigny | France | |
| Service de psychiatrie de l'enfant et de l'adolescent, CHRU Gabriel Montpied | Clermont-Ferrand | France | |
| Maison de Solenn, Cochin Hospital | Paris | France | |
| Centre Médico-psychologique, Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Hôpital La Grave, CHU Toulouse | Toulouse | France |
More Assistance Publique - Hôpitaux de Paris trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04206969 on ClinicalTrials.gov ↗ ← All trials in France